Oral Immunotherapy for Food Allergy

Wood RA

Pediatric Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, USA

Abstract

Food allergy is a potentially life-threatening condition with no approved therapies apart from avoidance and injectable epinephrine for treatment of acute allergic reactions. Oral immunotherapy (OIT) is an experimental treatment in which patients consume gradually increasing quantities of the food to which they are allergic in an attempt to induce some level of desensitization. While desensitization is possible in most patients, OIT carries significant risks for allergic reactions, and the ability to induce longer-term tolerance has not yet been established. This review focuses on selected studies of OIT for the treatment of common food allergies such as cow’s milk, hen’s egg, and peanut.


Resumen

La alergia alimentaria es una condición potencialmente mortal para la que no existen tratamientos aprobados, excepto la evitación y la epinefrina para tratar reacciones alérgicas graves. La inmunoterapia oral (OIT) es un tratamiento experimental en el cual los pacientes ingieren cantidades gradualmente crecientes del alimento al que son alérgicos, con el fin de inducir algún nivel de desensibilización. Si bien la desensibilización es posible en la mayoría de los pacientes, OIT conlleva riesgos importantes de reacciones alérgicas y la capacidad de inducir tolerancia a más largo plazo todavía no ha sido establecida. Este artículo de revisión se centra en una selección de estudios de OIT para el tratamiento de alergias a alimentos comunes, como son la leche de vaca, huevos de gallina y cacahuete.

Introduction

Food allergy is now estimated to affect up to 8% of children and up to 2%-3% of adults in the United States of America [1,2], where cow’s milk, hen’s egg, peanut, tree nut, wheat, soy, fish, and shellfish are the foods most often associated with food allergy [2]. Food allergy is potentially life-threatening and has a major impact on quality of life [3,4]. Avoidance is currently the only approved therapy, and, although effective, avoidance diets can be difficult and may also put children at risk of nutritional deficiencies and impaired growth [5,6]. While at least 80% of milk- and egg-allergic children are expected to achieve natural tolerance to these foods by adulthood, only 15%-20% of peanut- or tree nut–allergic individuals “outgrow” their allergies [7]. Peanut allergy is common in developed countries, affecting 1%-2% of children in the United States of America [4,8], and peanut is implicated in over half of all food allergy–related deaths in the United States of America [9,10]. Effective therapies for peanut and other common food allergies are therefore highly desirable.

What is Oral Immunotherapy?

Oral immunotherapy (OIT) involves mixing an allergenic food into a vehicle and consuming it in gradually increasing doses [11]. OIT protocols vary in the type of food and vehicle used, with some using commercially available foods in their natural forms (eg, liquid milk or peanut flour), while others use specifically prepared products such as dehydrated egg white. Currently, although OIT essentially uses food materials, research studies in the United States of America require investigational new drug approval, and forms of therapy regulated by the United States Food and Drug Administration require additional standards and safeguards. For example, allergenic proteins must be identified and quantified, and the product must be shown to be free of microbial contaminants.

Most OIT protocols include an initial escalation phase, followed by a dose build-up phase and maintenance phases, which may vary considerably depending on the study (Figure) [11]. The initial escalation phase is typically conducted over 1-2 days using rapid up-dosing, which starts from a very small dose (extremely unlikely to cause an adverse reaction) and progressing to a dose that is still likely safe for home administration. Generally, the initial doses are in microgram quantities of allergenic protein, which progress to several milligrams by the end of this phase. If well tolerated, the dose is escalated incrementally (usually biweekly or weekly) until a target maintenance dose is reached or the patient reaches dose-limiting symptoms. There is considerable variation between studies regarding the target maintenance dose, which ranges from 300 mg to 4000 mg. Maintenance therapy continues with daily administration in the home, and the length of maintenance therapy is heterogeneous, lasting from a few months to several years [12]. The Table illustrates some of the variability in study design in terms of maintenance dosing, length of therapy, and outcomes.

Efficacy of OIT

The potential efficacy of food OIT depends on the defined endpoints, including the ability to tolerate the treatment, the induction of a transient state of desensitization, and/or the development of a more durable state of clinical tolerance, which is often referred to as sustained unresponsiveness (SU) [13,14]. Desensitization is defined as a temporary increase in the threshold for reactivity, with maintenance of the desensitized state requiring continued consumption of the allergenic protein to prevent the reappearance of reactivity. In some trials, patients who are successfully desensitized are then required per protocol to restrict the allergenic food from their diet for a period of weeks to months, after which another oral food challenge is conducted to determine whether or not they have achieved SU. While all studies have demonstrated that the majority of patients treated with OIT can be successfully desensitized to a particular food, SU is less commonly achieved. This lack of sustained protection against allergic
symptoms has important implications for the future of oral immunotherapy and highlights the experimental nature of this treatment.

### Summary of Clinical Trials

#### Peanut OIT

The use of subcutaneous peanut immunotherapy was first reported in 1992, but this approach was abandoned owing to an unacceptable systemic reaction rate [15]. Following 2 case reports of successful peanut OIT in 2006 [16,17], the first open-label trial of peanut OIT was published in 2009 in a prospective cohort study [18,19], which showed successful desensitization and an overall reassuring safety profile, as well as immunologic changes consistent with those seen in other forms of immunotherapy. With a maintenance dose of 1800 mg of peanut protein, 93% of the 29 patients who completed the protocol were able to tolerate an oral challenge with a cumulative dose of 3.9 g of peanut protein at 36 months [18].

### Table. Representative OIT Trials

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Design</th>
<th>Patient Age</th>
<th>Maintenance Dose</th>
<th>Duration</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones et al [18]</td>
<td>2009</td>
<td>Open-label</td>
<td>1 - 16</td>
<td>1800 mg</td>
<td>36 months</td>
<td>93% passed 3.9 g peanut OFC</td>
</tr>
<tr>
<td>Blumchen et al [20]</td>
<td>2010</td>
<td>Randomized open-label</td>
<td>3 - 14</td>
<td>500 mg</td>
<td>7-day rush escalation, 8 weeks maintenance</td>
<td>64% reached their maintenance dose of 500 mg peanut</td>
</tr>
<tr>
<td>Varshney et al [21]</td>
<td>2011</td>
<td>Randomized, placebo-controlled</td>
<td>3 - 11</td>
<td>2000 mg</td>
<td>48 weeks</td>
<td>84% passed 5000 mg peanut OFC</td>
</tr>
<tr>
<td>Anagnostou et al [22]</td>
<td>2011</td>
<td>Open-label</td>
<td>4 - 18</td>
<td>800 mg</td>
<td>32 weeks</td>
<td>64% tolerated 6.6 g OFC</td>
</tr>
<tr>
<td>Anagnostou et al [23]</td>
<td>2014</td>
<td>Randomized, placebo-controlled</td>
<td>7 - 16</td>
<td>800 mg</td>
<td>26 weeks</td>
<td>62% tolerated 1400 mg challenge</td>
</tr>
<tr>
<td>Vickery et al [14]</td>
<td>2014</td>
<td>Open-label</td>
<td>1 - 16</td>
<td>Up to 4000 mg</td>
<td>Up to 5 years</td>
<td>One month after OIT stopped, 50% achieved SU to 5000 mg OFC</td>
</tr>
<tr>
<td>Narisetty et al [60]</td>
<td>2014</td>
<td>Randomized, placebo-controlled</td>
<td>7 - 13</td>
<td>2000 mg</td>
<td>12 months</td>
<td>Significantly greater increase in OFC threshold in OIT versus SLIT, low rate of SU</td>
</tr>
<tr>
<td>Vickery et al [25]</td>
<td>2016</td>
<td>Randomized clinical trial</td>
<td>9 - 36 months</td>
<td>300 vs 3000 mg</td>
<td>29 months (median)</td>
<td>Overall, 91% SU, no difference between doses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Egg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buchanan et al [28]</td>
</tr>
<tr>
<td>Vickery et al [29]</td>
</tr>
<tr>
<td>Burks et al [13]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Milk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Longo et al [41]</td>
</tr>
<tr>
<td>Skripak et al [42]</td>
</tr>
<tr>
<td>Martorell et al [46]</td>
</tr>
<tr>
<td>Keet et al [48]</td>
</tr>
</tbody>
</table>

Abbreviations: OFC, open food challenge; OIT, oral immunotherapy; SLIT, sublingual immunotherapy; SU, sustained unresponsiveness.
In 2011, Varshney et al [21] reported the first multicenter, randomized, double-blind, placebo-controlled study of peanut OIT. The study included 28 patients aged 1 through 16 who underwent treatment with peanut or placebo with a daily maintenance dose of 4 g for about 1 year. Three patients withdrew early owing to adverse reactions; however, in a posttreatment double-blind, placebo-controlled food challenge (DBPCFC), the 16 patients who completed active OIT were able to ingest a maximum cumulative dose of 5 g of peanut protein (~16 peanuts) compared with the placebo group of 9 patients, who tolerated a median of 280 mg. The study also showed a significant decrease in skin test responses, as well as changes in serum IL-5 and IL-13 levels and CD4+CD25+FoxP3+ regulatory T cells in the active group compared with the placebo group.

In 2011, Anagnostou et al [22] reported results from a prospective cohort study of peanut OIT, in which 22 children received a daily maintenance dose of 800 mg of peanut protein for 32 weeks. The authors demonstrated a significant increase in the peanut challenge threshold with 86% of patients tolerating up-dosing and 14/22 (64%) tolerating 6.6 g of peanut protein at the completion of treatment. In 2014, the same group completed a randomized controlled trial (RCT) with peanut OIT at a maintenance dose of 800 mg [23]. In the first phase, each arm underwent 26 weeks of peanut OIT versus peanut avoidance, after which patients underwent a food challenge to 1400 mg of peanut protein. In the active OIT group, 24 of 39 participants (62%) had no reaction compared with no participants in the control group. The second phase allowed participants in the control group to receive active peanut OIT, with 84% of the active group at the end of the first phase and 91% of the control group at the end of the second phase able to tolerate daily ingestion of 800 mg protein for 26 weeks.

The first study of SU following peanut OIT was published in 2014 [14]. Twenty-four patients aged 1 to 16 years completed OIT with maintenance dosing of 4000 mg of peanut protein for up to 5 years. One month after stopping OIT, 50% of the patients demonstrated SU to a 5000-mg oral challenge. Patients demonstrating SU were also found to have greater evidence of immunomodulation, with smaller wheals, lower peanut IgE levels, including Ara h 1 and Ara h 2, and lower ratios of peanut-specific IgE/total IgE. In another study that was designed primarily to compare peanut sublingual immunotherapy (SLIT) with OIT, while OIT was far superior to SLIT, only 4 of 20 patients on OIT were shown to have SU [24].

In a more recent open-label RCT analyzing peanut OIT in a population aged 9 to 36 months [25], patients were randomized to goal maintenance doses of 300 mg/d or 3000 mg/d. In the intent-to-treat analysis, 29 of 37 patients (78%) achieved SU 4 weeks after completing treatment, with similar rates in the 300-mg group (85%) and the 3000-mg group (71%) after a median treatment period of 29 months. Per protocol, 29 of 32 patients (91%) achieved SU. It was also reassuring that the therapy was well tolerated, even in children of such a young age.

**Egg OIT**

Two early studies from Patriarca et al [26,27] reported on small numbers of patients treated with egg OIT, demonstrating successful desensitization in most patients. In another early trial, Buchanan et al [28] reported on 7 children aged 14 months to 7 years who received 24 months of egg OIT at a maintenance dose of 300 mg of daily, with 57% passing an oral food challenge at completion of treatment. In a follow-up study at the same center, patients treated with a higher, individualized dose (median 2400 mg) for a median of 33 months had an SU rate of 75% (6 of 8 patients) 1 month after stopping treatment [29].

In one of the first randomized OIT trials, Staden et al [30] reported on 45 children who were treated with either egg or milk OIT, with maintenance dosing of 1.6 g/d or 3.5 g/d, respectively, or an avoidance diet as a control. Eleven of the patients were egg-allergic. Although the milk and egg results were not reported separately, after a median of 21 months of therapy, 16/25 (64%) were able to introduce the allergenic food into their diet, 9 with complete tolerance and 7 with partial tolerance, compared with 7 of 20 children (35%) in the control group. Morisset et al [31] also published a randomized study of 60 children with milk allergy and 90 children with egg allergy. Patients were randomized to OIT or allergen avoidance, and after 6 months of treatment, 69% of those receiving egg OIT were successfully desensitized.

In 2012, Burks et al [13] reported results from the first multicenter, double-blind, placebo-controlled trial of egg OIT in which 55 patients aged 5-11 years were treated with a maintenance dose of 2 g of egg protein, with egg DBPCFCs performed at 10 and 22 months. For those who did not experience a reaction at the 22-month challenge, OIT was discontinued for 6-8 weeks with a repeat food challenge to test for SU. At the 10-month DBPCFC, none of the placebo patients (n=15) were desensitized compared with 55% of those treated with active OIT. After 22 months of OIT, 30 of 40 patients (75%) were effectively desensitized, but only 11 (28%) demonstrated SU on rechallenge 6 to 8 weeks later.

Other studies of egg OIT included the small RCTs by Dello Iacono et al and Meglio et al, who reported desensitization rates of 80%-90% in children with severe egg allergy, and 2 studies using rush protocols with desensitization induced in as few as 5 days [32-35].

**Milk OIT**

As with egg, Patriarca et al [26,27] performed 2 small-scale trials and reported the first studies on milk OIT, with desensitization rates of 65.5% and 100%. In 2004, Meglio et al [36] performed a pilot study of 21 children treated with 6 months of OIT that resulted in a 72% success rate of tolerating a target dose of 200 mL of cow’s milk daily, with an additional 14% of patients achieving partial desensitization. Of note, after a 4-year follow up, 70% at least partially tolerated milk, with significant reductions in serum-specific cow’s milk IgE and skin prick test results [37]. A number of other nonrandomized milk OIT studies also demonstrated overall success in achieving desensitization [38-40].

As noted above for egg OIT, the first RCT of milk OIT was reported by Staden et al [30]. In 2008, Longo et al [41] reported an RCT of 60 children with a history of severe cow’s milk allergy and high CM-specific IgE levels who were randomized to milk OIT or avoidance. While all those in the control group failed the DBPCFC at the 1-year mark, 36% of treated patients...
Oral Immunotherapy for Food Allergy

doi: 10.18176/jiaci.0143

OIT using boiled noodles was safe and effective [53]. Concluded that even in patients with very severe wheat allergy, passed an OFC to assess SU 2 weeks later. The authors was achieved by 16 of the 18 patients, 11 of whom (61.1%) noodles that contained 5.2 g of wheat protein. The target dose was achieved by 16 of the 18 patients aged 24 to 36 months and demonstrated desensitization in 90% at 1 year. In 2012, Salmivesi et al [47] reported the results of an RCT in school-aged children, showing similar effectiveness for milk OIT.

In 2012, Keet et al [48] also published an open-label RCT comparing milk OIT with SLIT. All patients were initially treated with SLIT, after which they were randomized to continue SLIT or switch to OIT. The study demonstrated greater efficacy with OIT, as well as a higher incidence of significant adverse effects. The study also examined SU after stopping therapy for 1 and 6 weeks, showing that only 40% of patients passed an OFC when treatment was discontinued for 6 weeks and that 2 lost protection in the first week off therapy. An additional follow-up report on 32 patients from the study by Keet et al [49] on milk OIT showed that only 31% of patients appeared to be fully milk-tolerant 3 to 5 years after completing treatment, with many patients appearing to lose tolerance after successfully completing treatment, even some with demonstrated SU.

Over the past decade, many patients with milk allergy have been shown to tolerate milk that has been extensively heated; in addition, this exposure helps to promote eventual tolerance to unheated milk [50]. A recent study by Goldberg et al [51] sought to use this concept in patients who had been unable to tolerate milk OIT and were treated with OIT using baked milk. Unfortunately, in this highly select group of patients with severe milk allergy, only 3 of 14 achieved the primary outcome of tolerating 1.3 g of baked milk. Of the 11 treatment failures, 8 failed because of IgE-mediated reactions, and 3 did not complete the program because of non–IgE-mediated factors.

**OIT to Other Foods and Multiallergen OIT**

While most research to date has focused on milk, egg, and peanut, there is great interest in the potential to treat other common food allergies. Studies are currently ongoing using OIT to treat allergy to wheat, tree nut, fish, and possibly other food allergens. A recent study by Sato et al [52] investigated the efficacy of OIT in patients with wheat-induced anaphylaxis. The treatment was open-label with a historical control group of untreated patients, and the dose was 200 g of Japanese wheat noodles that contained 5.2 g of wheat protein. The target dose was achieved by 16 of the 18 patients, 11 of whom (61.1%) passed an OFC to assess SU 2 weeks later. The authors concluded that even in patients with very severe wheat allergy, OIT using boiled noodles was safe and effective [53]. There is also interest in the potential to treat multiple food allergies simultaneously, since so many children are allergic to more than 1 food. Numerous OIT studies with multiple food allergens are currently underway, some with and some without coadministration of omalizumab. To date, preliminary data from one study demonstrated similar reaction rates and efficacy comparing monotherapy with peanut to OIT based on up to 5 foods [54], while a second Phase 1 study demonstrated successful desensitization to multiple foods using rush OIT after pretreatment with omalizumab. Reaction rates were relatively low (median of 3.2 reactions per 100 doses) [55].

**Immunologic Changes With OIT**

The mechanisms by which OIT induces desensitization, and possibly longer-term effects, remain under active investigation. Studies have consistently demonstrated specific immunologic changes, including increases in food-specific IgG4 and decreased basophil and mast cell responsiveness [13,14,18,56]. Some studies have shown alterations in the binding pattern of antigen to antigen-specific IgE, either by reduction in the diversity of epitope recognition or altered IgE affinity [57]. After 6-12 months of OIT, there appears to be a shift away from Th2 cytokine production towards a proinflammatory profile characterized by increased production of IL-1β and TNF-α [18]. Syed et al demonstrated increased function of antigen-specific CD4+CD25+FoxP3+ regulatory T cells following OIT, thus supporting the theory of active suppression of immune responses [56,58].

Gorelik et al [59] studied the mechanisms and duration of suppression of immune responses during peanut immunotherapy reported in the study by Narisetty et al [60] and found that spontaneous and allergen-induced basophil reactivity, including IL-4 production, were suppressed during dose escalation and after 6 months of maintenance dosing. Many markers of immunologic suppression reversed after withdrawal of immunotherapy and, more surprisingly, in some cases during ongoing maintenance therapy. The authors concluded that while both peanut OIT and SLIT induce rapid suppression of basophil effector functions, dendritic cell activation, and Th2 cytokine responses during the initial phases of immunotherapy, in many patients suppression appeared to be transient.

Begin et al [61] addressed changes in allergen-specific T-cell phenotypes during immunotherapy. While prior studies have shown an overall skewing of the pathological Th2 response toward a normal Th1 or regulatory T-cell response, questions have been raised about the specificity of this approach and whether these changes result from a reprogramming of existing allergen-specific clones (re-education hypothesis) or from their replacement by different clones to determine the dominant response (replacement hypothesis). The authors undertook next-generation sequencing of peanut-proliferative TCRβ in patients undergoing peanut OIT and found an extremely diversified polyclonal response with a very small fraction of consistent clones over time.

**Safety of OIT**

Adverse reactions are very common in OIT, with rates that are similar for each of the foods studied to date. Reactions are
Adjunctive Therapies

Several potential adjunctive therapies to OIT have been studied, with the goal of improving both safety and efficacy. Two initial pilot studies have examined the use of omalizumab in combination with OIT, one with milk and the other with peanut [65,66]. In both cases, it is suggested that OIT can be escalated more rapidly when combined with omalizumab, although adverse reactions are still relatively common.

Two more recent RCTs also studied the adjunctive effects of omalizumab. In the first, Wood et al [67] studied the addition of omalizumab or placebo to open-label milk OIT. At the completion of treatment, 88.9% of the omalizumab-treated patients and 71.4% of the placebo-treated patients passed the 10-g "desensitization" OFC (P=.18). Two months later, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P=.42). Adverse reactions were significantly reduced during OIT escalation in omalizumab-treated patients with regard to the percentage of doses with symptoms (2.1% vs 16.1%, P=.0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P=.0008), and doses required to achieve maintenance (198 vs 225, P=.008). The authors concluded that omalizumab led to improvements in safety but not efficacy.

In the second study, open-label omalizumab was administered in a placebo-controlled study of peanut OIT [68]. After 12 weeks of treatment with omalizumab, patients underwent a rapid 1-day desensitization of up to 250 mg of peanut protein, followed by weekly increases up to 2000 mg. The median peanut dose tolerated on the initial desensitization day was 250 mg for omalizumab-treated patients compared with 22.5 mg for placebo-treated patients. Subsequently, 79% of those receiving omalizumab tolerated 2000 mg of peanut protein 6 weeks after stopping omalizumab compared with 12% of those receiving placebo (P<.01). Reaction rates were not significantly lower in omalizumab-treated patients than in placebo-treated patients (odds ratio, 0.57; P=.15), although omalizumab-treated patients were exposed to much higher peanut doses. The authors concluded that omalizumab enables patients with peanut allergy to be rapidly desensitized and that in most cases, this desensitization is sustained after omalizumab is discontinued.

It has also been suggested that probiotics may have adjuvant effects for inhalant allergen immunotherapy [69]. Tang et al [70] expanded this concept to food immunotherapy with a trial adding the probiotic Lactobacillus rhamnosus to peanut OIT or placebo. The primary outcome was induction of possible SU 2 to 5 weeks after discontinuing OIT, which was achieved in 82.1% of those receiving OIT and 3.6% of those receiving placebo. While these results are limited by the fact that the probiotic treatment was not placebo-controlled and the period off treatment was as short as 2 weeks, the proportion of patients achieving SU was higher than in other studies, thus raising the possibility that probiotics may truly enhance this effect.

Case reports and small open-label trials have been conducted with a number of other adjunctive therapies, including interferon gamma, ketotifen, and leukotriene receptor antagonists [71-75]. In 2013, a randomized single-blind placebo-controlled study of 6 patients undergoing peanut OIT showed that premedication with ketotifen at 2 mg twice daily might reduce the incidence of gastrointestinal symptoms during active OIT [73]. Furthermore, Takahashi et al [74] studied the use of montelukast with OIT in a retrospective study of 5 children, where leukotriene receptor antagonists appeared to help patients reach their target dose. Each of these possible adjunctive therapies requires further study.

Future Considerations/Conclusions

Food allergy is common and potentially life-threatening. Despite the significant impact of food allergy on patients and health care systems, there are currently no approved therapies for food allergy apart from strict avoidance. Milk, egg, and peanut OIT studies have consistently shown successful desensitization, although longer-lasting tolerance does not appear likely at this stage of investigation. Further mechanistic studies are needed to improve our understanding of the immunologic changes induced by OIT and to identify biomarkers of response. Safety is a significant concern, as adverse events are common during OIT, thus limiting its use in some patients. Incorporation of novel therapies such as modified food allergens, probiotics, and other immunomodulator therapies in conjunction with OIT is underway with the goals of improving both safety and efficacy. Larger, well-designed, randomized, placebo-controlled trials are needed to determine the efficacy and short- and long-term safety of OIT before it can be implemented in general clinical practice.
Funding

The author declares that no funding was received for the present study.

Conflicts of Interest

The author declares that he has received research support from the National Institutes of Health, Astellas, Aimmune Therapeutics, DBV, and HAL-Allergy.

References


